Table 2.
Characteristics of cancer survivors (n=14 358)
| n (%) | |
| Year of diagnosis | |
| 1970-4 | 2544 (17.7) |
| 1975-9 | 4069 (28.3) |
| 1980-6 | 7745 (53.9) |
| Age at diagnosis* | |
| 0-4 years | 5754 (40.1) |
| 5-9 years | 3200 (22.3) |
| 10-14 years | 2913 (20.3) |
| 15-20 years | 2491 (17.3) |
| Diagnosis | |
| Leukaemia | 4830 (33.6) |
| Brain cancer | 1876 (13.1) |
| Hodgkin’s lymphoma | 1927 (13.4) |
| Non-Hodgkin’s lymphoma | 1081 (7.5) |
| Kidney tumour | 1256 (8.7) |
| Neuroblastoma | 954 (6.6) |
| Soft tissue sarcoma | 1245 (8.7) |
| Bone cancer | 1189 (8.3) |
| Therapy† | |
| Surgery | 909 (7.3) |
| Radiation | 33 (0.3) |
| Chemotherapy | 816 (6.5) |
| Chemotherapy and radiation | 1459 (11.7) |
| Chemotherapy, radiation, and surgery | 5550 (44.3) |
| Radiation and surgery | 1479 (11.8) |
| Chemotherapy and surgery | 2274 (18.2) |
| Anthracycline dose† | |
| No anthracycline | 7385 (51.4) |
| <250 mg/m2 | 1931 (13.4) |
| ≥250 mg/m2 | 2834 (19.7) |
| Cardiac radiation dose† | |
| No cardiac radiation | 4160 (29) |
| <500 cGy | 4897 (34.1) |
| 500 to <1500 cGy | 832 (5.8) |
| 1500 to <3500 cGy | 1398 (9.7) |
| ≥3500 cGy | 988 (6.9) |
| Bleomycin† | |
| No | 11818 (82.3) |
| Yes | 756 (5.3) |
| Cisplatin† | |
| No | 11836 (82.4) |
| Yes | 738 (5.1) |
| Cyclophosphamide† | |
| No | 6880 (47.9) |
| Yes | 5694 (39.7) |
| Vincristine† | |
| No | 3543 (24.7) |
| Yes | 9031 (62.9) |
*Mean=6.0 years, range=0-20 years.
†All treatment data were missing for 1111 participants (308 refused and 803 had not yet signed medical release). In addition, 727 individuals were missing one or more data entry for surgery, chemotherapy, or radiation. Each treatment variable includes total counts, reflecting complete data available for that type of treatment.